Literature DB >> 10404713

The measurement of premenstrual mood symptoms.

M Steiner1, D L Streiner, S Steinberg, D Stewart, D Carter, C Berger, R Reid, D Grover.   

Abstract

INTRODUCTION: To aid in the diagnosis and management of premenstrual syndromes, dozens of symptom measurement instruments have been created and several methods for classifying clinically important change in symptoms have been defined. While the diagnosis of premenstrual dysphoric disorder (PMDD) has become standardized through the application of research criteria, consensus amongst investigators as to the instruments best able to confirm the diagnosis and measure treatment effects has yet to be reached.
OBJECTIVE: To determine the performance and inter-correlations of three prospective symptom rating scales used to establish severity of premenstrual mood symptoms and measure efficacy during a treatment trial for premenstrual dysphoria.
METHODS: Single item visual analogue scales (VASs) for irritability, tension, depression and mood swings were used in combination with the Premenstrual Tension Syndrome Observer (PMTS-O) and Self-Rating (PMTS-SR) scales to measure the severity of premenstrual mood symptoms at baseline and during treatment.
RESULTS: Premenstrual mood symptoms as measured by VASs significantly correlated with PMTS-0 and PMTS-SR scale scores (range 0.70 to 0.82, P < 0.001). All scales were sensitive to premenstrual symptom worsening (which is a required characteristic of this disorder) and revealed differences in effects of treatment on premenstrual mood symptoms (P < 0.001).
CONCLUSIONS: VASs in combination with the PMTS-O are low in burden to the client, reliable, valid and sensitive to change. In light of the current debates regarding instruments most appropriate for the classification and measurement of treatment effects in women diagnosed with premenstrual dysphoria, further refinement of these scales is warranted.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404713     DOI: 10.1016/s0165-0327(98)00121-9

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  17 in total

1.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

2.  [SIPS--screening instrument for premenstrual symptoms. The German version of Premenstrual Symptoms Screening Tool to assess clinically relevant disturbances].

Authors:  D Bentz; M Steiner; G Meinlschmidt
Journal:  Nervenarzt       Date:  2012-01       Impact factor: 1.214

Review 3.  Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management.

Authors:  M Steiner
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

4.  A shortened psychophysical task to quantify irritability: the Reactive Irritability Scale II (RIS-II).

Authors:  Martha M Faraday; Peter M Scheufele; Kelly J Vander Ley; Neil E Grunberg
Journal:  J Behav Med       Date:  2005-02

5.  Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.

Authors:  Kimberly A Yonkers; Susan G Kornstein; Ralitza Gueorguieva; Brian Merry; Kari Van Steenburgh; Margaret Altemus
Journal:  JAMA Psychiatry       Date:  2015-10       Impact factor: 21.596

Review 6.  Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus.

Authors:  Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen Freeman; Uriel Halbreich; Khaled M K Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; Peter Schmidt; Meir Steiner; John Studd; Kimberley Yonkers
Journal:  Arch Womens Ment Health       Date:  2011-01-12       Impact factor: 3.633

7.  Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Teri B Pearlstein; Kevin M Bellew; Jean Endicott; Meir Steiner
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

8.  Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder.

Authors:  Sheryl S Smith; Yevgeniy Ruderman; Cheryl Frye; Gregg Homanics; Maoli Yuan
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

9.  Posttraumatic Stress Disorder, Hostile Cognitions, and Aggression in Iraq/Afghanistan Era Veterans.

Authors:  Elizabeth E Van Voorhees; Paul A Dennis; Lydia C Neal; Terrell A Hicks; Patrick S Calhoun; Jean C Beckham; Eric B Elbogen
Journal:  Psychiatry       Date:  2016       Impact factor: 2.458

Review 10.  Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?

Authors:  Teri Pearlstein
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.